Azasetron or an analog thereof, or a pharmaceutically acceptable salt and/or solvate thereof, for treating severe or profound sudden sensorineural hearing loss (SSNHL) in a subject in need thereof. In particular, azasetron or an analog thereof, or a pharmaceutically acceptable salt and/or solvate thereof, for treating severe or profound SSNHL in a subject suffering from severe or profound SSNHL associated with (i) a hearing threshold at baseline corresponding to a pure tone audiometry (PTA) at baseline equal to or greater than 70 dB, preferably equal to or greater than 80 dB, more preferably equal to or greater than 90 dB; (ii) a hearing loss at baseline equal to or greater than 91 dB corresponding to a profound hearing loss according to the American Speech-Language-Hearing Association (ASHA) classification; (iii) a hearing loss at baseline affecting frequencies equal to or lower than 2000 Hz; and/or (iv) the presence of vertigo at baseline.
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the preservation of residual hearing following cochlear implantation in a subject in need thereof, wherein the subject has a hearing threshold at baseline in at least one ear corresponding to an unaided audiometric threshold at baseline greater than 65 dB, the unaided audiometric threshold being expressed as the average of at least 3 values each determined at a different frequency within the range from 0.25 kHz to 0.75 kHz.
The present invention relates to a recombinant adeno-associated virus (rAAV) vector encoding connexin 26 (CX26). The present invention further relates to the use of said AAV vector in the treatment of genetic hearing loss.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
The present invention relates to an isolated nucleic acid sequence comprising at least two copies of a miRNA target site of the miR183 family having a sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 21, or SEQ ID NO: 24, or a sequence having at least 90% identity with any one of SEQ ID NO: 1, SEQ ID NO: 21, or SEQ ID NO: 24. The present invention also relates to a vector comprising a regulatory element comprising at least one copy of said miRNA target site of the miR183 family. The isolated nucleic acid sequence and the vector may be particularly useful for controlling the expression of a gene of interest, for example when designing and developing gene therapies.
The present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment of severe or profound sudden sensorineural hearing loss (SSNHL) in a subject in need thereof. In particular, the present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment of severe or profound SSNHL in a subject suffering from severe or profound SSNHL associated with (i) a hearing threshold at baseline corresponding to a pure tone audiometry (PTA) at baseline equal to or greater than 70 dB, preferably equal to or greater than 80 dB, more preferably equal to or greater than 90 dB; (ii) a hearing loss at baseline equal to or greater than 91 dB corresponding to a profound hearing loss according to the American Speech-Language- Hearing Association (ASHA) classification; (iii) a hearing loss at baseline affecting frequencies equal to or lower than 2000 Hz; and/or (iv) the presence of vertigo at baseline.
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Disclosed is a method for treating ear disorders, including the administration of (+)-azasetron, or a pharmaceutically acceptable salt and/or solvate thereof.
The therapeutic use of azasetron or an analogue thereof for treating and/or preventing a lesion in the central auditory nervous system (CANS) in an individual. The treatment of lesions in the CANS with azasetron also prevents, inhibits, and/or reduces the loss of the central auditory neuron cells in the brainstem.
The present invention relates to the therapeutic use of azasetron or an analogue thereof for treating and/or preventing a lesion in the central auditory nervous system (CANS). The inventors show that treatment of lesions in the CANS with azasetron allows reducing the loss of neurons in the brainstem.
terttert-butyl azetidin- 3-yl(methyl)carbamate, or another N-protected N-methylazetidin-3-amine, and performing the following steps: (a) coupling reaction of both compounds in dimethyl sulfoxide in presence of potassium carbonate to afford an intermediate protected compound; and (b) deprotection of the protected compound to afford 2-isobutyl-6-(3-(methylamino)azetidin-1-yl)pyrimidin-4-amine. The invention also relates to a process for manufacturing the intermediate protected compound, wherein deprotection step (b) is omitted. The invention also relates to the compounds obtained from the processes according to the invention.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
12.
(+)-azasetron for use in the treatment of ear disorders
Disclosed is a method for treating ear disorders, including the administration of (+)-azasetron, or a pharmaceutically acceptable salt and/or solvate thereof.
The present invention relates to a compound for use for preventing ototoxicity in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition or a medicament comprising the compound of the invention.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical products for use in science, bases (chemical
products), chemical products used for the manufacture of
pharmaceutical products. Pharmaceutical and veterinary products for the treatment
and/or prevention of diseases of the ears, tablets for
pharmaceutical use; medicines for human and veterinary use;
chemical and biological preparations for medical or
pharmaceutical use, preparations of microorganisms for
medical use; capsules for medicines. Academic and clinical research services in the scientific,
biological, medical and technological fields provided by
engineers and scientists, chemical analysis, clinical
studies; computer system design, these services provided in
the field of medical research relating to vestibular
disorders.
18.
Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Chemicals for use in science used in the manufacture of pharmaceuticals and prevention's medicines for pathologies of the inner ear, Bases, namely chemical preparations used for the manufacture of pharmaceuticals and prevention's medicines for pathologies of the inner ear, Chemical products for use in the manufacture of pharmaceuticals, namely additives for use in the manufacture of pharmaceuticals, chemicals for use in the pharmaceutical industry.
(2) Pharmaceutical and veterinary preparations for the treatment and prevention of diseases of the ears, Capsules for pharmaceutical purposes for the treatment and prevention of pathologies of the inner ear; Medicines for human or veterinary purposes for the treatment and prevention of pathologies of the inner ear; Chemical and biological preparations for medical and pharmaceutical purposes for the treatment and prevention of pathologies of the inner ear, Micro-organism cultures for medical use; Capsules for medicines for the treatment and prevention of pathologies of the inner ear. (1) Clinical and academic research in the fields of science, biology, medicine and technology provided by engineers and scientists in the field of medical research relating to inner ear disorders, Chemical analysis, Clinical research in the field of medical research relating to inner ear disorders; Design of computer systems, The aforesaid services being provided in the field of medical research relating to vestibular disorders.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical preparations for use in science; chemical preparations in the nature of bases for use in science; chemical preparations used for the manufacture of pharmaceutical products Pharmaceutical and veterinary products for the treatment and/or prevention of diseases of the ears; tablets for pharmaceutical use for the treatment of pathologies of the inner ear; medicines for human and veterinary use for the treatment of pathologies of the inner ear; chemical and biological preparations for medical or pharmaceutical use for the treatment of pathologies of the inner ear; preparations of microorganisms for medical use for the treatment of pathologies of the inner ear; capsules for use as medicines, for the treatment of pathologies of the inner ear Academic and clinical research services in the scientific, biological, medical and biotechnological fields related to inner ear disorders and provided by engineers and scientists; chemical analysis; clinical studies, namely, conducting scientific feasibility studies, preclinical studies and clinical trials; computer system design related to the medical field and the pathologies of the inner ear; all of the foregoing services provided in the field of medical research relating to vestibular disorders
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
The present invention relates to a compound that impairs or prevents accumulation of platinum drugs within vestibular hair cells and/or vestibular primary neurons for use in treating platinum drugs induced vestibulotoxicity.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/4168 - 1,3-Diazoles having a nitrogen atom attached in position 2, e.g. clonidine
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
23.
CALCINEURIN INHIBITORS FOR USE IN THE TREATMENT OF LESIONAL VESTIBULAR DISORDERS
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemicals for use in science, Bases (chemical preparations), Chemical products for use in the manufacture of pharmaceutical preparations. Pharmaceutical and veterinary preparations for the treatment and/or prevention of diseases of the ears, Capsules for pharmaceutical purposes; Medicines for human or veterinary purposes; Chemical and biological preparations for medical and pharmaceutical purposes, Micro-organism cultures for medical use; Capsules for medicines. Clinical and academic research in the fields of science, biology, medicine and technology provided by engineers and scientists, Chemical analysis, Clinical research; Design of computer systems, The aforesaid services being provided in the field of medical research relating to vestibular disorders.
